Table 2.
Comparison of donors, recipients, and transplant characteristics between GS 0–10% and GS > 10% transplanted allografts.
| Glomerulosclerosis | |||
|---|---|---|---|
| 0–10% | >10% | p-Value | |
| N | 7796 | 1730 | |
| Donor | |||
| Age (years) | 60.7 ± 7.1 | 60.5 ± 6.8 | 0.18 |
| Male (%) | 46.7 | 42.7 | 0.002 |
| Black (%) | 28.8 | 28.3 | 0.66 |
| Diabetes (%) | 26.5 | 33.1 | <0.001 |
| Hypertension (%) | 79.0 | 81.5 | 0.02 |
| BMI (kg/m2) | 28.8 ± 6.9 | 29.2 ± 7.5 | 0.04 |
| Creatinine (mg/dL) before kidney procurement | 1.2 ± 1.0 | 1.2 ± 0.6 | 0.85 |
| Donor after cardiac death (%) | 10.0 | 7.0 | <0.001 |
| HCV antibody positive (%) | 5.8 | 2.5 | <0.001 |
| Cause of death (%) | |||
| Cerebrovascular accident | 78.1 | 80.4 | 0.04 |
| Machine perfusion (%) | 49.9 | 50.2 | 0.82 |
| Expanded criteria donor (%) | 85.4 | 87.3 | 0.04 |
| Recipient | |||
| Age (years) | 61.5 ± 9.8 | 62.2 ± 9.6 | 0.003 |
| Male (%) | 64.0 | 63.1 | 0.48 |
| Black (%) | 36.4 | 37.9 | 0.26 |
| BMI | 27.9 ± 5.3 | 28.1 ± 5.4 | 0.35 |
| Diabetes (%) | 47.2 | 47.4 | 0.86 |
| Dialysis duration (%) | |||
| Preemptive | 9.8 | 9.1 | 0.40 |
| <1 years | 8.7 | 7.8 | 0.25 |
| 1–3 years | 29.6 | 27.9 | 0.16 |
| >3 years | 49.4 | 52.4 | 0.02 |
| PRA (%) | |||
| <10 | 81.7 | 83.9 | 0.03 |
| 10–60 | 12.0 | 10.6 | 0.10 |
| >60 | 5.9 | 4.6 | 0.03 |
| Missing | 0.5 | 1.0 | 0.01 |
| Transplant | |||
| HLA DR mismatch (%) | |||
| 0 | 8.2 | 7.4 | 0.30 |
| 1 | 39.0 | 36.9 | 0.10 |
| 2 | 52.8 | 55.7 | 0.03 |
| Cold ischemic time (hours) | 19.5 ± 9.4 | 20.3 ± 9.4 | <0.001 |
| Transplant period | |||
| 2005–2007 | 28.6 | 26.2 | 0.05 |
| 2008–2010 | 33.8 | 32.8 | 0.40 |
| 2011–2014 | 37.6 | 41.0 | 0.008 |
| Induction therapy (%) | |||
| Thymoglobulin | 46.1 | 52.0 | <0.001 |
| Alemtuzumab | 14.7 | 14.2 | 0.59 |
| Basiliximab | 18.9 | 18.6 | 0.79 |
| Other induction | 7.6 | 7.3 | 0.67 |
| No induction | 16.3 | 11.7 | <0.001 |
GS, glomerulosclerosis; HCV, hepatitis C virus; BMI, body mass index; PRA, panel reactive antibody; HLA, human leukocyte antigen.